RecruitingRelapsed Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaNon-Hodgkin Lymphoma

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

Eligible age

18+ yrs

Accepts

All genders

Locations

21 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of rondecabtagene autoleucel (ronde-cel) also known as LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive large B-cell lymphoma.

Sponsor: Lyell Immunopharma, Inc.

You may qualify if…

✓ 1. Age 18 years or older
✓ 2. Willing and able to provide written informed consent
✓ 3. Histologically confirmed LBCL, including the following types defined by the World Health Organization (WHO 2022) or International Consensus Classification (2022)
✓ 4. Received at least two prior lines of therapy for Cohorts 1, 2, and 4 and one prior line of therapy for Cohort 3
✓ 5. Relapsed or refractory disease.
✓ 6. At least 1 measurable lesion (per Lugano classification)
✓ 7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 or ECOG 0 to 2 (Cohort 5)
✓ 8. Absolute neutrophil count (ANC) ≥ 1000/µL

You may not qualify if…

✕ 1. History of malignancy other than non-melanoma skin cancer or carcinoma in situ unless disease-free for at least 3 years
✕ 2. Active central nervous system involvement
✕ 3. History of cardiac lymphoma involvement or Epstein-Barr virus (EBV)+ lymphoma
✕ 4. Ongoing or impending oncologic emergency
✕ 5. Recent systemic anti-cancer therapy or radiation
✕ 6. Ongoing non-hematologic toxicities due to prior therapy
✕ 7. History of allogeneic stem cell or solid organ transplantation
✕ 8. Autologous stem cell transplantation within 6 weeks